| Ytd | 34.39% | |
| 1y | -18.01% |
| Open | 2.85 | Prev Close | 2.89 | Low | 2.74 | High | 2.88 | Mkt Cap | 282.93M |
| Vol | 524.81K | Avg Vol | 2.49M | EPS | -1.23 | P/E | -2.35 | Forward P/E | -0.53 |
| Beta | 2.10 | Short Ratio | 6.70 | Inst. Own | 70.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 2.95 | 200-d Avg | 2.69 | 1yr Est | 3.67 |
EDIT News
Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin
CAMBRIDGE, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneeri
Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-hu
CAMBRIDGE, Mass. , May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneeri
Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo ge
Editas Medicine (EDIT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus
EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve e
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should tak
Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have received an average rating of
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
JPMorgan Chase and Co. cut its holdings in Editas Medicine, Inc. (NASDAQ: EDIT) by 23.0% in the unde
CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer
Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have been given a consensus rating
Editas Medicine has been on fire over the trailing-12-month period. However, the stock has been crus
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a
On Wednesday, 220 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its
On Tuesday, 298 companies achieved new lows for the year.
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i
Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua
On Tuesday, 951 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Wednesday, 348 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Highs On Wednesday